Wednesday 24 July, 2024Press Release: July 24th, 2024, Bath, United Kingdom: ReadyGo Diagnostics Ltd. (ReadyGo™), an innovator in diagnostic technology solutions, is excited to announce a co-development agreement with SureScreen Diagnostics Ltd., a global leader in rapid diagnostics to research, develop, and commercialise a groundbreaking product aimed at the drink spike testing market.
This partnership will leverage ReadyGo's advanced Sampler technology and proprietary dried reagent technology, combined with SureScreen's proven assays for drug detection, to deliver an easy-to-use consumer testing solution.
The collaboration aims to address a growing public safety concern by providing a compact, portable device that can be easily deployed in various environments, including bars, clubs, and other licensed premises.
Key Features of the New Testing Assay:
I. Comprehensive Drug Testing in Decentralised Settings:
The new test will offer extensive coverage for detecting various drugs commonly used to spike drinks such as GHB (Gamma Hydroxybutyrate), rohypnol (Flunitrazepam) and ketamine (Ketalar).
II. Rapid Turnaround Time:
The test will provide quick results in just a few minutes, helping someone to make immediate decisions. This fast response can help prevent harm and keep individuals safe.
III. User-Friendly Operation:
Designed for ease of use by non-specialised consumers, the test features simplified sample collection and processing. Its intuitive design and ease-of-use means it can be used anywhere and by anyone.
"This collaboration represents a significant step forward in our mission to provide innovative and accessible testing solutions to as many people as possible," said Ben Cobb, CEO of ReadyGo Diagnostics Limited. "By combining our innovative technology with SureScreen's expertise in drug detection, we are creating a product that meets a growing and critical need for reliable drink spike testing for consumers who may be in vulnerable situations."
George Newham, Research and Development Manager of SureScreen Diagnostics Limited, added, "We are excited to partner with ReadyGo Diagnostics on this important initiative. Our joint effort will deliver a powerful tool that enhances public safety and aligns with the evolving landscape of testing in licensed premises."
This co-development initiative underscores both companies' commitment to innovation and public health, ensuring that timely interventions are accessible to all. The partnership aims to bring to market a highly effective and user-friendly testing solution that can make a real difference in preventing drug-related harm.
- End –
About ReadyGo Diagnostics Ltd.
ReadyGo Diagnostics is at the forefront of the new consumer focused diagnostics industry, innovating and commercialising breakthrough sample collection devices and diagnostic solutions. Our commitment to accessibility drives us to develop technologies that simplify testing for everyone. The Sampler, our proprietary device, redefines sample preparation by seamlessly integrating collection and processing into one easy-to-use disposable, ensuring consistent and reliable results across molecular, biochemical, and lateral flow assays. Our flagship molecular diagnostic platform, Geo, revolutionises testing by enabling low-cost, decentralised results in under 30 minutes. Further extending our innovative approach, Snapshot merges our efficient sample handling with an integrated molecular test, delivering a comprehensive diagnostic solution in a single device.
For more information, please refer to the website: www.readygotest.com
About SureScreen Diagnostics
Established in 1996, SureScreen have been providing proactive, bespoke diagnostic solutions to organisations for over twenty seven years. We believe that early, accurate drug screening and health diagnosis significantly reduces the time to intervention, leading to improved safety while greatly benefiting people’s health. We are an award-winning business providing quality rapid diagnostic equipment & services around the globe. We provide tailored services and products across the UK and Europe that allow for fast, cost-effective, accurate results to meet and exceed customers’ expectations at a fair price. SureScreen Diagnostics’ state-of-the-art operational site in the UK enables quick and reliable design, production and services to customers throughout Europe and the Rest of the World.
With its global reach, SureScreen Diagnostics continues to research and develop cutting-edge products with world-first biodegradable tests. More recently, Surescreen Diagnostics has produced and manufactured lateral flow tests for Mpox and the first dual Influenza + Covid test to be approved for use in the UK.
Additional information on the Company can be found at www.surescreen.com
Contacts
ReadyGo Diagnostics Ltd.
Ben Cobb, Chief Executive Officer
Ben Reed, Chief Commercial Officer
info@readygotest.com
SureScreen Diagnostics Ltd.
David Campbell, Director
George Newham, Research and Development Manager
Craig McMillan, Head of Sales and Marketing
info@surescreen.com
